MAGEA3 and neoplasm: In another study, 16 melanoma patients received a dendritic vaccine loaded with a cocktail of gp100 peptides, MART-1 (melan-A or melanoma antigen recognized by T-cells 1), tyrosinase, MAGE-1 (melanoma-associated antigen 1), or MAGE-3 (melanoma-associated antigen 3) and 4 patients were treated with a dendritic vaccine loaded with tumor lysate.